ACVR1B抗体—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 80 μg, Lane: A172 cells, Primary antibody: P00047(ACVR1B Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 40 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P00047(ACVR1B Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gasrtic cancer tissue using P00047(ACVR1B Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

The ACVR1B antibody targets the Activin Receptor Type-1B (ACVR1B), a transmembrane serine/threonine kinase receptor belonging to the TGF-β superfamily. ACVR1B plays a critical role in mediating signaling pathways initiated by ligands such as activins and growth differentiation factors (GDFs). Upon ligand binding, ACVR1B forms a complex with type II receptors, activating downstream SMAD proteins (SMAD2/3) to regulate gene expression involved in cell proliferation, differentiation, and apoptosis. This receptor is widely expressed in tissues, including skeletal muscle, bone, and the immune system, and is implicated in diverse physiological processes, such as embryonic development, tissue repair, and metabolic homeostasis.

ACVR1B dysregulation is linked to pathological conditions. Overactivation may contribute to fibrosis, cancer progression, or muscular disorders, while loss of function can disrupt normal tissue maintenance. Antibodies against ACVR1B are essential tools for studying its expression, localization, and function in both normal and diseased states. They enable applications like Western blotting, immunohistochemistry, and flow cytometry, aiding in the exploration of ACVR1B's role in signaling crosstalk, therapeutic targeting, or biomarker discovery. Additionally, neutralizing antibodies are investigated for therapeutic potential in diseases driven by aberrant TGF-β/activin signaling, such as metastatic cancers or fibrotic disorders. Research on ACVR1B antibodies continues to advance understanding of its mechanistic contributions and clinical relevance.